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Background: Propolis is a honey bee product which contains many active compounds, such as CAPE or chrysin,
and has many beneficial activities. Recently, its anti-tumor properties have been discussed. We have tested whether
the ethanolic extract of propolis (EEP) interferes with temozolomide (TMZ) to inhibit U87MG cell line growth.
Methods: The U87MG glioblastoma cell line was exposed to TMZ (10-100 μM), EEP (10-100 μg/ml) or a mixture of
TMZ and EEP during 24, 48 or 72 hours. The cell division was examined by the H3-thymidine incorporation, while
the western blot method was used for detection of p65 subunit of NF-κB and ELISA test to measure the
concentration of its p50 subunit in the nucleus.
Results: We have found that both, TMZ and EEP administrated alone, had a dose- and time-dependent inhibitory
effect on the U87MG cell line growth, which was manifested by gradual reduction of cell viability and alterations in
proliferation rate. The anti-tumor effect of TMZ (20 μM) was enhanced by EEP, which was especially well observed
after a short time of exposition, where simultaneous usage of TMZ and EEP resulted in a higher degree of growth
inhibition than each biological factor used separately. In addition, cells treated with TMZ presented no changes in
NF-κB activity in prolonged time of treatment and EEP only slightly reduced the nuclear translocation of this
transcription factor. In turn, the combined incubation with TMZ and EEP led to an approximately double reduction
of NF-κB nuclear localization.
Conclusions: We conclude that EEP presents cytotoxic properties and may cooperate with TMZ synergistically
enhancing its growth inhibiting activity against glioblastoma U87MG cell line. This phenomenon may be at least
partially mediated by a reduced activity of NF-κB.
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Glioblastoma is a common primary brain tumor which
demonstrates a high proliferation rate and an aggressive
growth pattern and is largely resistant to chemotherapy
[1]. One of the most promising drugs for brain tumor
therapy is temozolomide (TMZ) (8-carbamoyl-3-
methylimidazo [5,1-d]- 1,2,3,5-tetrazin-4 (3H)-one), an
oral alkylating agent belonging to imidazotertrazines [2],
which exhibits anti-cancer properties against malignancies* Correspondence: bromatos@umb.edu.pl
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distribution, and reproduction in any medium[1,3,4]. According to Uzzaman et al, [5] the average sur-
vival of patients with glioblastoma after TMZ treatment is
22 months, which is still not enough to be satisfied with
the therapy.
Propolis is composed of flavonoids, fatty, aliphatic and
aromatic acids, steroids, aminoacids and vitamins, such as
B1, B2, E, C, flavonoids, alcohols, terpenes, sugars and
esters [6,7]. A natural honeybee product, propolis has been
demonstrated in many studies due to its antibacterial,
antifungal [8-10], antiviral [11] hepatoprotective and
immunostimulative activities [12]. It has been showed that
the efficacy of propolis depends on the contents of the
mentioned ingredients in particular flavonoids [13,14].ioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Markiewicz-Żukowska et al. BMC Complementary and Alternative Medicine 2013, 13:50 Page 2 of 9
http://www.biomedcentral.com/1472-6882/13/50The anti-cancer activities of propolis have been
presented in various culture cell lines, such as mammary
carcinoma (MCA), human epithelial carcinoma (HeLa),
human leukemia (HL-60, CI41, U937), human ovarian car-
cinoma (SK-OV-3), human lung carcinoma (NCI-H358),
human hepatocellular carcinoma (HepG2), human cervical
cancer (ME180) and human pancreatic cancer (PANC-1,
BxPC-3) cells [15-19]. The anti-tumor activities of propolis
were exerted by proliferation arrest and/or induction of
apoptosis in a variety of cancer cells.
One of the benefits of anticancer therapy is the induc-
tion of apoptosis by the kinases activation and the re-
lease of cytochrome c into the cytosol, which activates
caspases [15,16]. This causes the cell cycle arrest by the
suppression of complexes of cyclins and cyclin-
dependent protein kinases in cancer cells [17-19].
A recent study showed that TMZ administered to-
gether with propolis [20] enhanced the sensitivity of
human brain cancer cells, indicating that the com-
bination of TMZ with natural products may be more
effective in glioma therapy than using TMZ alone. It
seems that naturally bioactive compounds may have
a co-operative action with chemotherapeutics. The
combination of TMZ and natural anti-cancer agents
is suggested as a new approach in Central Nervous
System (CNS) tumor treatment.
The aim of our study was to examine the influence of
EEP on TMZ anti-cancer activity in U87MG human glio-
blastoma cell line, expressed as changes in cell viability
and proliferation. We have also established a correlation
between cell growth inhibition by TMZ, EEP and their
combination and nuclear factor type B (NF-κB) activity.
Methods
Reagents
TMZ, thiazolyl blue tetrazolium bromide (MTT) and di-
methyl sulfoxide (DMSO) were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Propolis of Apis mellifera
was collected in the Podlasie region (the north-west part
of Poland) in August 2010. To obtain ethanolic extract,
propolis was crushed and 20 g were extracted in a
shaker with 80 g of 95% ethanol for 6 h in a darkened
place. The extract was filtered, concentrated and
lyophilized. The dry extract was protected from light
and kept frozen at −20°C. The yield of the prepared ex-
tract (% w/w), in terms of the starting material, was 16.3.
The extract was dissolved in DMSO and prepared as
1 mg/ml stock solution in medium.
Cell culture
The studies were performed on a human glioblastoma
cell line U87MG (HTB-14) purchased from American
Type Culture Collection, (Rockville, MD). The cells were
maintained in Eagle's Minimal Essential Medium Eaglewith L-glutamine (292 mg/L) (PAA Laboratories GmbH,
Pasching, Austria) supplemented with 10% fetal bovine
serum (PAA Laboratories GmbH, Pasching, Austria)
without antibiotics in a humidified incubator at 37°C
and 5% CO2 atmosphere. Sub-confluent cells were
detached with Trypsin-EDTA solution (PAA Laborator-
ies GmbH, Pasching, Austria) in calcium-free phosphate
buffered saline (PBS) (Biomed, Lublin, Poland) and
counted in hemocytometers.
Cytotoxicity assay
The effects of TMZ (10, 20, 50, 100 μM), EEP (10, 20,
30, 50, 100 μg/ml) and EEP combined with TMZ
(20 μM) on the viability of glioblastoma cell line
(U87MG) were studied after 24 h, 48 h and 72 h of
treatment. Cells were seeded into 96-well plates in a vol-
ume of 200 μl per well at density of 2 × 104 cells/well
and grown for 22 h at 37°C in a humidified 5% CO2 in-
cubator. Cell viability was measured by a quantitative
colorimetric assay using MTT [21]. The data was
expressed as a percentage of control.
H3-thymidine incorporation
U87MG cells were plated in 24-well plates and exposed to
a medium containing DMSO (control), TMZ, EEP or EEP
with TMZ. Cells were cultured 20, 44 and 68 hours prior
to the addition of 0.5 μCi of H3-thymidine per well. After
4 hours of incubation, the medium was removed and cells
were washed twice with cold 0.05 M Tris-HCl and 5%
trichloroacetic acid, scrapped and transferred to a scintilla-
tion cocktail. The level of incorporated H3-thymidine was
assessed using Beckman liquid scintillation counter.
Western blot
Scrapped cells were centrifuged and frozen in -80°C
until use. The nuclear proteins were extracted using
Nuclear and Cytoplasmic Extraction Reagents (NE-
PER) kits (Thermoscientific) according to the manual
provided by the manufacturer. 50 μg of protein from
each sample was separated by 12% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and immobilized onto the PVDF membrane
(Millipore). The immunoblots were incubated with
primary antibodies, at a dilution of 1:500 for p65 (Cell
Signaling Technology) and 1:1000 for H3 (histone H3)
(Sigma-Aldrich) overnight and then with the second-
ary antibodies conjugated with alkaline phosphatase
(AP) (Cell Signaling Technology, Sigma–Aldrich, re-
spectively). Immunoreaction was developed with nitro
blue tetrazolium- 5-Bromo-4-chloro-3-indolyl phos-
phate (NBT-BCIP) system. The optical density of the
bands was established using INTAS device. H3 levels
were considered as an internal control of the amount
of loaded protein. The results were normalized and
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calculated from five independent experiments.
Enzyme-linked immunosorbent assay (ELISA)
Nuclear extracts in amount of 40 μg per well, utilized
previously in Western blotting (as described above) were
used in ELISA. The experiments were performed using
DNA-binding ELISAs for activated NF-κB transcription
factors (TransAM) NFκB p50 (Active Motif ) in accord-
ance with the instructions of manufacturer. The results
are shown as a percentage of the control value and are
calculated from three independent experiments.
Statistical analysis
The data was expressed as a mean value of percent of
control ± standard deviation. All data was analyzed
using STATISTICA, Version 9.0 using the Student-t test
to calculate the value significance. P values < 0.05 were
accepted as statistically significant.
Results
The effect of TMZ on the viability of glioblastoma cell line
(U87MG)
After 24 h of incubation, TMZ at concentrations 10 μM-
50 μM did not significantly alter the viability of the
U87MG cell line (Figure 1). The marked reduction of vi-
able cell number (79% of control) at that time point was
observed only when TMZ was used in concentration of
100 μM. After 48 h of exposure, the viability of glioma
cells decreased gradually with increasing TMZ
concentrations reaching 74.40% of control for the lowest
concentration and 54.90% for the highest. A strong re-
duction in the number of living cells in relation to con-
trol (from 47.30% to 8.60%) was reported after 72 h of
treatment with TMZ for all TMZ concentrations used.
The effect of cell growth inhibition by TMZ potentiated
with time of exposure for each amount of the drug.Figure 1 Viability of U87MG (% of control) after incubation
with temozolomide. The results are presented as a percentage of
control. ## p < 0.01, ### p < 0.001 vs. control; ● ● p < 0.01, ● ● ●
p < 0.001 vs. equivalent of 24 h groups;○○○ p < 0.001 vs.
equivalent of 48 h groups.The effects of EEP and EEP with TMZ on the viability of
glioblastoma cell line (U87MG)
Basing on the comparative analysis of the effects of dif-
ferent TMZ concentrations on U87MG cell growth, we
established that 20 μM of TMZ is the most appropriate
concentration which should be used in further
experiments (Figure 1). Additionally, we selected the
concentration close to the content of TMZ in brains of
patients with gliomas. It was shown, using a microdialysis
study, that the peak concentration of TMZ in brain
interstitium was about 0.6 μg/ml (3 μM) [22] and TMZ
concentrations in a normal brain calculated from
pharmacokinetic model ranged from 1.8 to 3.7 μg/ml
(9 μM – 20 μM) [23].
We found that EEP induces significant dose- and
time-dependent reductions of cell viability in compari-
son with control (Figure 2). Interestingly, EEP was a
stronger inducer of U87MG cell growth arrest than
TMZ, starting from the concentration of 30 μg/ml for
24 hours and 20 μg/ml for 48 and 72 hours of exposition
(Figure 2).
The combined administration of TMZ at a concentra-
tion of 20 μM and EEP at various concentrations
brought diverse results. Clear, synergistic action of EEP
and TMZ was noted for 24-hour treatment. The cell via-
bility was greater for all concentrations of separately-
administrated EEP (from about 100% to 44%) and
20 μM TMZ (about 95%) in comparison with the
combined administration of 20 μM TMZ and a
corresponding dose of EEP (from about 74% to 34%, re-
spectively from the lowest to the highest concentration
of EEP) (Figure 2A). We have noted that 48 hours after
exposure, a reduction of cell viability by a combined ad-
ministration of EEP and TMZ remained on a similar
level as that revealed by EEP alone (from about 67% to
10% for propolis and from 57% to 14% of control for
TMZ with EEP, respectively) and in all cases was higher
than the effect of TMZ (20 μM) alone (65% of control)
(Figure 2B). 72 hours after exposure, the result of EEP ac-
tion on U87MG treated simultaneously with TMZ was
dependent on the concentration of EEP. Its lower
concentrations (10-30 μg/ml) exerted a lesser effect on
the reduction in the number of living cell treated at the
same time with TMZ than TMZ alone (from about 42%
to 28% of control for TMZ with EEP, respectively and
about 22% of control for TMZ alone). In contrast, 50 and
100 μg/ml of EEP were able to inhibit TMZ-treated cell
growth stronger than TMZ alone (about 18% and 7% of
control, respectively). However, the use of a combined
administration of TMZ and EEP led to a better cell via-
bility for 20-50 μg/ml of EEP in comparison with prop-
olis used at those concentrations alone (36% to 18% of
control for TMZ with EEP and 16% to 5% of control for
EEP alone). Only at the concentration of 10 μg/ml EEP
Figure 2 Viability of U87MG (% of control) after incubation with EEP and temozolomide. Control – (1), Temozolomide (2 - TMZ 20 μM), EEP
(3 - 10 μg/ml, 5 - 20 μg/ml, 7 - 30 μg/ml, 9 - 50 μg/ml, 11 - 100 μg/ml), EEP administered together with temozolomide (4 – EEP 10 μg/ml + TMZ
20 μM, 6 - EEP 20 μg/ml + TMZ 20 μM, 8 - EEP 30 μg/ml + TMZ 20 μM, 10 - EEP 50 μg/ml + TMZ 20 μM, 12 - EEP 100 μg/ml + TMZ 20 μM). Viability of
U87MG cells after 24 (A), 48 (B) and 72 (C) hours of incubation. The results are presented as a percentage of control. A/#p < 0.05, ##p < 0.01,
###p < 0.001, vs. control; *p < 0.05, ***p < 0.001, vs. TMZ; ▲ p < 0.05, ▲ ▲ p < 0.01, ▲ ▲ ▲ p < 0.001, vs. EEP; B/ ###p < 0.001, vs. control; *p < 0.05;
**p < 0.01; ***p < 0.001, vs. TMZ; ▲ ▲ p < 0.01, vs. EEP; C/###p < 0.001, vs. control; *p < 0.05, ***p < 0.001, vs. TMZ; ▲ p < 0.05, ▲ ▲ ▲ p < 0.001, vs. EEP.
All statistical analysis were performed using Student-t test.
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bination with TMZ (42% of control) than alone (49% of
control). For 100 μg/ml of EEP both types of treatments
showed similar effects (about 7% of control for TMZ and
EEP and 7% of control for EEP alone) (Figure 2C).
The effect of EEP and EEP with TMZ on H3-thymidine
incorporation in the glioblastoma cell line (U87MG)
TMZ revealed a strong inhibitory potential to U87MG
cells after a 24-hour exposition leading to an almost 60%decrease of H3-thymidine incorporation versus control
(Figure 3A). At the same time, EEP exhibited a minor
ability to enhance proliferation and a combination of
TMZ and EEP was less powerful to arrest cell division
(about 80% of control) than TMZ alone (about 40% of
control). 48-hour exposition did not cause a reduction of
proliferation rate of TMZ treated cells, whereas EEP
lowered DNA synthesis by approximately 20% in relation
to control. Moreover, a combination of EEP with TMZ
exhibited the synergistic effect decreasing proliferation
Figure 3 The effects of EEP or/with temozolomide on
H3- thymidine incorporation in U87MG cells. EEP (P 30 μg/ml),
temozolomide (TMZ 20 μM), EEP administered together with
temozolomide (P+TMZ). H3- thymidine incorporation after 24 (A), 48
(B) and 72 (C) hours of incubation. The results are presented as a
percentage of control. Significant changes obtained from the
Student-t test are indicated at the columns with: A/ ##p < 0.01, vs.
control; *p < 0.05, **p < 0.01, vs. TMZ; ▲ p < 0.05, vs. EEP; B/ #p < 0.05,
###p < 0.001, vs. control; ***p< 0.001, vs. TMZ; ▲ ▲ p< 0.01, vs. EEP; C/
##p < 0.01; ###p < 0.001, vs. control.
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the treatment of U87MG cells with TMZ alone did not
alter H3-thymidine incorporation in comparison with
control. In turn, EEP used alone caused about 20% re-
duction in cell division versus control and a combined
treatment of EEP and TMZ led to about 30% of
proliferation decline (Figure 3C).
The effect of EEP and EEP with TMZ on NF-κB activity in
glioblastoma cell line (U87MG)
We examined whether there is a correlation between a
reduced viability and proliferation of the glioblastoma
cells and the activity of NF-κB. The U87MG cells were
incubated in medium containing TMZ (20 μM) or EEP
(30 μg/ml) alone or a combination of TMZ and EEP
(20 μM and 30 μg/ml, respectively) during 72 hours.
Using the western blot method for detection of p65subunit of NF-κB (Figure 4A) and ELISA test to measure
the concentration of its p50 subunit (Figure 4B) in the
nucleus, we noted a perfect correlation of results
obtained for both subunits. We found that TMZ did not
alter the NF-κB activity in U87MG cells since nuclear
localization of both p65 and p50 remained at the level
similar to control. Moreover, EEP alone led to only a
slight decrease of nuclear content of both subunits. On
the other hand, the incubation of cells with mixture of
TMZ and EEP resulted approximately in 50% reduc-
tion of NF-κB activity, which clearly suggests a syner-
gic effect of EEP and TMZ. To verify the ELISA
specificity, we performed the pre-incubation of the
control nuclear extracts with wild-type or mutated
consensus sequence for NF-κB. The test of the compe-
tition showed a dramatic decline of p50 signal when a
wild-type sequence was used and only a minor de-
crease using a mutated sequence.
Discussion
In this work we have presented the cooperative effect of
temozolomide and ethanolic extract of propolis on the
growth of glioblastoma U87MG cell line. We examined
the ethanolic extract of propolis because it is a common
dietary supplement. Patients during chemotherapy may
be tempted to self-medicate with natural supplements.
There is data indicating that some dietary supplements
may impair the activity of anticancer drugs. Therefore,
the simultaneous intake of chemotherapeutics and folk
medicine products by oncogenic patients might lead to
the worsening the effects of therapy [24]. This kind of
extract is commonly used in the cell cultured (glioblast-
oma, neuronal cells) experiments [20,25,26]. The main
idea of our study was to verify whether propolis, a
widely-consumed natural product, interferes with TMZ,
a drug approved in glioma therapy. TMZ acts on cells in
the cell cycle stage independent manner [2], producing
DNA lesions and the methyl guanine (O6-MG) adduct is
considered to play an essential role in TMZ cytotoxicity
[27]. The main enzyme responsible for glioblastoma
multiform (GBM) resistance to TMZ is O6-MG-DNA
methyltransferase (MGMT), which takes off the methyl
adducts from the DNA [15]. Although MGMT gene pro-
moter is entirely methylated in U87MG cells and the
protein remains on undetectable level [28], these cells
reveal a partial resistance to TMZ.
We have found concentration- and time-dependent
decrement in viability of U87MG cells treated both with
TMZ and EEP. Similar results were obtained by Borges
et al [20], who showed antiproliferative properties of
Tubi-bee propolis in glioblastoma and fibroblast cell
lines and its synergistic action with TMZ. An amount of
evidence shows that propolis causes a reduction of can-
cer cell growth due to proliferation arrest and apoptosis.
Figure 4 The effects of EEP or/with temozolomide on NFκB activity in U87MG cells. EEP (30 μg/ml), temozolomide (TMZ 20 μM), EEP
administered together with temozolomide (TMZ + EEP). NFκB activity: A/ protein p65 based on the Western blot analysis, B/ protein p50 based
on the Elisa method. The results are presented as a percentage of control. Significant changes obtained from the Student-t test are indicated at
the columns with: A and B/ ##p < 0.01, vs. control; *p < 0.05, vs. TMZ.
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and the geographic region where propolis comes from
[29]. The inhibition of DNA synthesis was reported for
Turkish propolis, which reflected its anti-tumor influ-
ence [30]. Ethanolic extract of Brazilian propolis
administrated to U937 lymphoma cells caused a reduced
cell growth and inhibition of DNA, RNA and protein
synthesis [31] and Brazilian red propolis eliminated 100%
of PANC-1 cell line, when added to the cell medium [32].
The mechanism by which propolis supports TMZ anti-
cancer activity is difficult to elucidate due to a great
number of its components. Many active substances, such
as quercetin, CAPE or chrysin [33], may be involved in a
cytotoxic effect of propolis, and most of them have
not been fully tested yet. The analysis of propolis
obtained from Podlasie region revealed enrichment in
CAPE and chrysin (manuscript under revision). These
two compounds are known to exhibit particularly high
biological activity. Interestingly, CAPE and chrysin
bring a minor effect on cell growth when used separ-
ately than crude propolis [34]. This observation
provides the basis for studies of the whole propolisextract rather than its individual ingredients, expecting
that multi-factor activity may bring a stronger and
more complex effect on cancer.
NF-κB is an essential survival factor for many glio-
blastomas including U87MG cell line [35]. Glioblast-
omas responded to NF-κB inhibition by reducing the
growth rate and induction of apoptosis. Moreover,
U87MG cells grafted into mice formed a tumor, which
was reduced in size by 40% by blocking NF-κB signal-
ing [36]. Propolis contains compounds, such as CAPE
[16] or chrysin [37], which can inhibit this transcription
factor activity. Taking into account the strong impact
on NF-κB activation presented by propolis-derived
compounds we verified whether propolis from Poland
modulates the NF-κB translocation to the nucleus in
U87MG cells exposed simultaneously to TMZ. NF-κB
transcription factor is a dimmer, which may consist of
subunit p65 (RelA), p50, p52, c-Rel and RelB, where the
most common set is p65-p50. NF-κB is anchored in the
cytoplasm in its inactive form by coupling to the inhibi-
tory protein of nuclear factor type B (IκB). When
activated, nuclear signal localization (NLS) of NF-κB
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binds to the promotor regions of NF-κB-responsive
genes [38]. In our studies we have found that EEP had
only a modest effect on NF-κB nuclear localization in
U87MB cells, which could be a consequence of too low
concentrations of NF-κB-inhibiting compounds in the
extract we used in our experiments. TMZ revealed no
influence on the transcription factor activity. Interest-
ingly, a combined administration of TMZ and EEP led to
50% reduction of NF-κB nuclear translocation.
Chaturvedi et al [39] in their review mention that NF-κB
overactivity is frequently found in different types of
cancers and the reduction of its transcriptional action
could serve as a treatment supplementary to chemother-
apy. Indeed, it was shown that preventing the conditional
activation of NF-κB inhibited melanoma development in
mice [40].
To elucidate how TMZ and propolis cooperate to
reduce NF-κB activation is a complex problem. The
expression of NF-κB may be regulated basing on p53-
dependent mechanism [41]. Interestingly, an important
feature of most of gliomas is the lack of mutation in
p53 gene, which is also characteristic of U87MG cell
line [42]. It was reported that the downregulation of
p65 subunit in the squamous cell carcinoma of the
head and neck cell lines required a presence of p53
protein [43]. Moreover, p53 augmented highly in U87
cells after exposure to TMZ [44]. Thus, a slight and
not significant effect of propolis on the reduction of
NF-κB activity may be potentiated by p53 stimulated
by TMZ. It seems that Akt-NF-κB relation may also
be important in gliomas. Although the epidermal
growth factor receptor/ phosphatidylinositol-3 kinases/
protein Kinase B (EGFR/PI3K/Akt) pathway is not
mutated in U87MG cell line [45], these cells contain
phosphatase and tensin homolog (pten) deletion [46], an
inhibitor of Akt-mediated signaling [47]. Zhang et al [48]
showed that an activated EGFR/Akt pathway positively
influenced NF-κB signaling in U87MG cells. This is es-
pecially important since TMZ can stimulate PI3K/Akt
signal transduction [49]. However, it was also shown
that TMZ induced increase of Akt activation is rather
marginal [50] in U87MG cells, which may explain our
results, where TMZ did not alter NF-κB activity. It is
likely that propolis exerts an antagonistic effect on Akt
signaling since its components were shown to inhibit
both NF-κB activation and Akt phosphorylation
[51,52]. Propolis may then interfere with the TMZ-
dependent PI3K/Akt signaling leading to partial de-
crease of NF-κB activity.
Conclusions
In this study we have shown that EEP collaborates with
temozolomide promoting the inhibition of glioblastomacell growth in comparison to these two agents used sep-
arately. The potentiation of anticancer activity of
temozolomide by EEP may be mediated by synergistic
influence of both agents on reduction of NF-κB activity.
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